Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Mar;63(3):363–366. doi: 10.1038/bjc.1991.86

Effects of anthracycline derivatives on hepatic neoplastic nodules of Lewis lung carcinoma and colon adenocarcinoma 26.

M Iigo 1, K Nishikata 1, Y Nakajima 1, A Hoshi 1
PMCID: PMC1971864  PMID: 2003977

Abstract

Five anthracycline derivatives, i.e. doxorubicin, epirubicin, pirarubicin, aclarubicin and a new fluorinated anthracycline derivative (ME2303), were tested for antitumour activity in mice with hepatic neoplastic nodules of Lewis lung carcinoma and colon adenocarcinoma 26. Intravenous administrations of pirarubicin and ME2303 on day 4 or days 4, 8 and 12 in mice with hepatic neoplastic nodules of Lewis lung carcinoma rendered more than 50% of mice tumour-free over wide ranges of nontoxic doses, whereas a few mice were cured by treatment with doxorubicin and no mice were cured by treatment with epirubicin or aclarubicin. Moreover, when ME2303 was administered at 50 mg kg-1 on days 7, 11 and 15 to six mice bearing more advanced hepatic tumours, five were cured, while pirarubicin and doxorubicin never achieved cure. Furthermore, in mice with hepatic neoplastic nodules of colon adenocarcinoma 26, ME2303 also showed a marked antitumour effect compared to pirarubicin or doxorubicin. Two or three injections of ME2303 starting from day 7 conferred a greater antitumour effect than did more fractionated or single-dose regimens.

Full text

PDF
363

Images in this article

365Figure 2
on p.365

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arcamone F. Clinically useful doxorubicin analogues. Cancer Treat Rev. 1987 Dec;14(3-4):159–161. doi: 10.1016/0305-7372(87)90002-8. [DOI] [PubMed] [Google Scholar]
  2. Cassinelli G., Configliacchi E., Penco S., Rivola G., Arcamone F., Pacciarini A., Ferrari L. Separation, characterization, and analysis of epirubicin (4'-epidoxorubicin) and its metabolites from human urine. Drug Metab Dispos. 1984 Jul-Aug;12(4):506–510. [PubMed] [Google Scholar]
  3. Hoshi A., Iigo M., Nakamura A., Yoshida M., Kuretani K. Antitumor activity of 1-hexylcarbamoyl-5-fluorouracil in a variety of experimental tumors. Gan. 1976 Oct;67(5):725–731. [PubMed] [Google Scholar]
  4. Iguchi H., Tone H., Ishikura T., Takeuchi T., Umezawa H. Pharmacokinetics and disposition of 4'-O-tetrahydropyranyladriamycin in mice by HPLC analysis. Cancer Chemother Pharmacol. 1985;15(2):132–140. doi: 10.1007/BF00257523. [DOI] [PubMed] [Google Scholar]
  5. Israel M., Seshadri R., Koseki Y., Sweatman T. W., Idriss J. M. Amelioration of adriamycin toxicity through modification of drug-DNA binding properties. Cancer Treat Rev. 1987 Dec;14(3-4):163–167. doi: 10.1016/0305-7372(87)90003-x. [DOI] [PubMed] [Google Scholar]
  6. Kopper L., Van Hanh T., Lapis K. Experimental model for liver metastasis formation using Lewis lung tumor. J Cancer Res Clin Oncol. 1982;103(1):31–38. doi: 10.1007/BF00410303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Oki T., Matsuzawa Y., Yoshimoto A., Numata K., Kitamura I. New antitumor antibiotics aclacinomycins A and B. J Antibiot (Tokyo) 1975 Oct;28(10):830–834. doi: 10.7164/antibiotics.28.830. [DOI] [PubMed] [Google Scholar]
  8. Tsuchiya T., Takagi Y., Ok K., Umezawa S., Takeuchi T., Wako N., Umezawa H. Syntheses and antitumor activities of 7-O-(2,6-dideoxy-2-fluoro-alpha-L-talopyranosyl)-daunomycinone and -adriamycinone. J Antibiot (Tokyo) 1986 May;39(5):731–733. doi: 10.7164/antibiotics.39.731. [DOI] [PubMed] [Google Scholar]
  9. Tsuchiya T., Takagi Y., Umezawa S., Takeuchi T., Komuro K., Nosaka C., Umezawa H., Fukatsu S., Yoneta T. Synthesis and antitumor activities of 14-O-acyl derivatives of 7-O-(2,6-dideoxy-2-fluoro-alpha-L-talopyranosyl)adriamycinone. J Antibiot (Tokyo) 1988 Jul;41(7):988–991. doi: 10.7164/antibiotics.41.988. [DOI] [PubMed] [Google Scholar]
  10. Tsuruo T., Yusa K., Sudo Y., Takamori R., Sugimoto Y. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines. Cancer Res. 1989 Oct 15;49(20):5537–5542. [PubMed] [Google Scholar]
  11. Umezawa H., Takahashi Y., Kinoshita M., Naganawa H., Masuda T., Ishizuka M., Tatsuta K., Takeuchi T. Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiot (Tokyo) 1979 Oct;32(10):1082–1084. doi: 10.7164/antibiotics.32.1082. [DOI] [PubMed] [Google Scholar]
  12. Weiss R. B., Sarosy G., Clagett-Carr K., Russo M., Leyland-Jones B. Anthracycline analogs: the past, present, and future. Cancer Chemother Pharmacol. 1986;18(3):185–197. doi: 10.1007/BF00273384. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES